Zhejiang ACEA Pharmaceutical Co. Ltd.
Quick facts
Phase 3 pipeline
- STI-1558 · Diabetes
STI-1558 is a small molecule drug that targets the SGLT2 receptor.
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: